---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-000823"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:24:59.193855+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biofrontera receives Nasdaq deficiency notice for bid price below $1.00 for 34 days

## Summary
- Nasdaq notice on Dec 31, 2025: common stock not compliant with Listing Rule 5550(a)(2) due to closing bid below $1.00.
- Company has 180 calendar days, until June 30, 2026, to regain compliance by closing at $1.00+ for 10 consecutive days.
- If not cured, company may qualify for second 180-day period by meeting other continued listing standards and indicating intent to cure via reverse stock split.
- Failure to cure could lead to delisting; company plans to monitor and consider available options.
- No immediate impact on trading; Biofrontera common trades on Nasdaq under symbol BFRI.

## SEC filing metadata
- accession: 0001493152-26-000823
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315226000823/0001493152-26-000823-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315226000823/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-000823
- JSON: https://secwatch.observer/filing/0001493152-26-000823.json
- Plain text: https://secwatch.observer/filing/0001493152-26-000823.txt

## Source-grounded claims
- claim_id: c11de82306d3c83b38945a4b35ccb623155811c0
  claim: Biofrontera Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  evidence_excerpt: December 31, 2025, Biofrontera Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company’s common stock was less than $1.00 per share for the previous 34 consecutive business days. The notice has no present impact on the listing or trading of the Company’s securities on The Nasdaq Capital Market. Un
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315226000823/0001493152-26-000823-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.